

Index

2D offline imaging (ultrasound), 36–37	anti-Müllerian hormone (AMH) candidate gene approach, 9–10 clinical applications, 53 defined, 52 in differential diagnosis of menstrual irregularity, 53–54 future of, 56 genome-wide association study (GWAS), 14 in international classification criteria (2018), 48 in pathogenesis of menstrual irregularity, 52–53 as PCOS diagnostic marker, 54–55 potential clinical uses for, 55 ultrasound and, 34 in utero, 63–64	key patient messages for, 98 support groups, 100 bilateral laparoscopic ovarian drilling (BLOD), 112 bilateral ovarian wedge resection (BOWR), 2–3, 110. <i>See also</i> polycystic ovary syndrome (PCOS) ovarian surgery bisphenol A (BPA), 83 breast cancer, 193
adrenal androgen complex pathophysiology of, 67 heritability of, 75–76 steriodogenesis, 67–68 adrenal androgen excess and PCOS and adrenal dysfunction, 69, 70–71 cortisol metabolism abnormalities, 71–72 factors contributing to, 70 glucose–insulin axis, 73–74 obesity and, 74–75 ovaries and, 72–73 oxygenated, 69 spideniology of, 68–69 advanced glycation end products (AGEs), 81 adverse childhood experiences (ACEs) and depression, 164 androgen receptor (AR). <i>See also</i> hyperandrogenism candidate gene approach, 10 genome-wide association study (GWAS), 14–15 androgens and endometrial cancer, 197 animal models and PCOS background, 60–61 pathogenetic mechanism, 62 research findings, 61–62 anovulation. <i>see</i> menstrual irregularity lifestyle interventions, 102 prevalence of, 102 anovulation clinical treatment complications, 107–108 first-line, 106 second-line, 106–107 anovulation pharmacological interventions anti-estrogens, 103–104 aromatase inhibitors, 103 gonadotropins, 105 insulin sensitizers, 104–105	anti-Müllerian hormone (AMH) levels, 3 anti-Müllerian hormone type 2 receptor (AMHR2) candidate gene approach, 9–10 genome-wide association study (GWAS), 14 anxiety in PCOS prevalence of, 165 risk factors for, 165 studies, 177–178 treatment, 165 aromatase inhibitors, 117 aromatase inhibitors for anovulation, 103 assisted reproductive technology (ART) complications, 123–124 bariatric surgery endoscopic, 154 and fertility, 156 history of, 153 laparoscopic, 153–154 mechanisms of action, 154–155 pediatric, 156–157 and PCOS, 155–156, 157 risks from, 154 Barker hypothesis, 60 behavior modification strategies in PCOS treatment exercise, 96–98 health literacy, 98–100	cancer breast, 193 endometrial, 179–180, 189–193 ovarian, 195 candidate gene approach limitations of, 8–9 to PCOS, 8 and polymorphisms, 59–60 SNPs identified in GWAS studies, 11 candidate gene approach studies AMH and AMHR, 2, 9–10 gonadotropins, 9 inflammation and, 11–13 metabolism and, 10 sex steroid metabolism and AR, 10 cardiovascular disease (CVD) cardiac echocardiographic parameters, 175 dyslipidemia, 174–175 endocrine disruptive chemicals (EDCs) and, 88–89 hypertension and, 175 as one of leading causes of women’s death, 174 in PCOS offspring, 139 PCOS risk factors, 175–176 clomiphene citrate (CC), 103–104, 106, 116–117 cognitive behavioral therapy (CBT), 164 combined oral contraceptive pill (COCP), 124 dehydroepiandrosterone (DHEA), 69 depression and PCOS prevalence of, 162–163 risk factors for, 163–164 studies, 177–178 treatment, 164–165

Index

- diabetes. *See also* insulin resistance
adrenal androgen excess and, 73–74
endocrine disruptive chemicals (EDCs) and, 86–88
obesity and, 150–151
pediatric, 172
PCOS and, 8
diabetes, type II, 171–172
diagnostic criteria
epidemiology, 21–22
history of, 3, 4–6
obesity as, 151–152
diethylstilbestrol (DES), 83
disordered eating. *See* eating disorders (ED) and PCOS
duodeno-jejunal diversion surgery, 153–154
dyslipidemia, 174–175, 197
eating disorders (ED) and PCOS
prevalence of, 166
risk factors for, 166
studies, 178
treatment, 166
endocrine disruptive chemicals (EDCs)
chemical particularities, 82–83
common, 80–81
defined, 80
exposure challenges, 83
sources of exposure, 80–82
endocrine disruptive chemicals (EDCs) and PCOS
cardiovascular disease (CVD), 88–89
correlation between, 83–84
diabetes and, 87–88
female reproduction hormones, 83–86
obesity and, 86–87
endometrial cancer, 179–180, 189–193
endometrial cancer risk factors
androgens, 197
dyslipidemia, 197
gene and protein expression, 197
insulin resistance and, 196
luteinizing hormone (LH), 196–197
obesity, 196
endoscopic sleeve gastropasty (ESG), 154
epigenetic etiology (PCOS)
animal models, 60–62
Barker hypothesis, 60
human studies, 62–63
ethnicity
PCOS and, 26, 48–49
and PCOS genetics, 59
exercise strategies for PCOS, 96–98
follicle-stimulating hormone (FSH)
complications, 107–108
for ovarian priming, 144
for ovulation induction, 103–105
foregut theory, 155
freeze-only strategy in IVF, 126
FSHR gene, 9, 14
genetics of PCOS
adrenal androgen and, 75–76
etiology of, 8
candidate gene approach, 9–13, 59–60
common architecture across different phenotypes, 8–17
depression and, 164
ethnicity, 59
gene identification approaches, 8
genome-wide association study (GWAS), 13–16
inheritance in, 6
inheritance patterns, 59–60
micro RNAs (miRNAs), 17
phenome-wide association studies (PheWAS), 15–17, 59
genome-wide association study (GWAS)
AMH and AMHR, 2, 14
background, 8
gonadotropins, 13–14
metabolism and, 15–16
sex steroid metabolism and AR, 14–15
gestational diabetes mellitus (GDM)
as long-term PCOS effect, 172
and PCOS, 133
gonadotropin-releasing hormone (GnRH), 124
gonadotropins
in candidate gene approach, 9
in GWAS, 13–14
IVF selection, 124–125
versus laparoscopic surgery, 117
for ovulation induction, 105, 106–107
hindgut theory, 155
Hippocrates, 1
hormones in female reproduction
and environmental toxins
hyperandrogenism, 83–84
hypothalamus–pituitary–ovary control actions, 85
ovary changes, 84–85
perinatal exposure, 85–86
human studies for genetic etiology
for PCOS
amniotic fluid, 63
background, 62
placental, 63
umbilical cord blood, 63
hyperandrogenism, 46–48, 83–84, 121–122. *See also* androgen receptor
hyperinsulinaemia
and endometrial cancer, 196
insulin resistance and, 171
hypertension and CVD, 175
in vitro fertilization (IVF)
ovarian hyperstimulation syndrome, 123–124
as third-line treatment, 121
in vitro fertilization (IVF) strategies
combined oral contraceptive pill (COCP), 124
freeze-only, 126
gonadotropin-releasing hormone (GnRH), 124
gonadotropin selection, 124–125
metformin, 126–127
pre-ovulatory trigger, 125
in vitro maturation (IVM), 127
in vitro maturation (IVM)
in cancer patient, 143–144
for fertility preservation, 144
future research, 147
goal to replicate in vivo process, 143
history of, 142
and IVF, 127
neonatal outcomes, 147
as OHSS elimination strategy, 127
oocyte collection procedure, 144–145
oocyte maturation procedure, 145–146
and PCOS, 143
stimulation protocols, 144
infertility
and endometrial cancer, 179
PCOS and, 22
inflammation and candidate gene approach, 11–13
insulin resistance. *See also* diabetes and endometrial cancer, 196
hyperinsulinemia and, 171
insulin sensitizers for anovulation, 104–105. *See also* metformin
International PCOS Network, 5–6
laparoscopic electrocautery of the ovaries (LEO), 107
laparoscopic gastric banding, 153
laparoscopic ovarian surgery
versus aromatase inhibitors, 117
versus clomiphene citrate (CC), 116
versus clomiphene citrate (CC) and metformin, 116–117
efficacy of, 116
versus gonadotropins, 117
history of, 110

- versus metformin, 116
- multi-needle intervention, 113
- transvaginal hydrolaparoscopy (THL), 112
- unilateral/bilateral, 112
- laparoscopic sleeve gastrectomy, 153
- laser surgery (ovarian), 111
- letrozole, 103
- Leventhal, Michael
 - 1934/35 paper of, 2
 - bilateral ovarian wedge resection (BOWR), 110
 - biography of, 1
 - research of, 1–2
- lifestyle interventions
 - anovulation, 102
 - behavior modification strategies, 95–96
 - for depression, 164
 - dietary recommendations, 94
 - health literacy, 98–100
 - importance of, 92–93, 122
 - management of healthy lifestyle, 94–95
 - obesity, 93–94
 - support groups, 100
- luteinizing hormone (LH), 196–197
- Maimonides, 1
- menopause and PCOS, 49
- menstrual irregularity. *See also*
 - anovulation
 - anti-Müllerian hormone (AMH), 52–54
 - and ovulatory dysfunction, 45–46
 - PCOS and, 23
- metabolic syndrome
 - after PCOS, 172
 - pediatric, 172
 - PCOS and, 8
- metabolism
 - candidate gene approach, 10
 - genome-wide association study (GWAS), 15–16
- metformin, 62, 74, 104, 116–117, 126–127. *See also* insulin sensitizers for anovulation
- microRNAs (miRNAs), 17
- natural selection and PCOS, 6
- neonatal outcomes
 - in PCOS, 136
 - in vitro maturation (IVM), 147
- obesity
 - adrenal androgen excess, 74–75
 - bariatric surgery for, 153–157
 - causes of, 150
 - defined, 150
 - degrees of, 150
 - and diabetes, 150–151
 - dietary recommendations, 94
 - and endometrial cancer, 179, 196
 - and gestational diabetes mellitus (GDM), 133
- obesity and PCOS
 - anxiety and, 165
 - as diagnostic criteria in, 151–152
 - eating disorders (ED) and, 166
 - fasting lipid protein testing for, 174–175
 - lifestyle recommendations, 93–94
 - as long-term effect, 172–174
 - pediatric, 174
 - PCOS and, 8, 22
 - pharmacology for, 152–153
 - regulation of, 151
 - risks of, 122–123
- obstructive sleep apnea (OSA), 176–177
- oocyte maturation procedure (IVM)
 - culture media, 145–146
 - embryo culture/transfer, 146
 - fertilization methods, 146
- oral contraceptives
 - for depression, 164–165
 - for IVF, 124
- ovarian cancer, 195
- ovarian enlargement, 3
- ovarian hyperstimulation syndrome (OHSS), 123–124, 142, 143
- ovarian priming, 144
- ovarian stroma, 33
- ovarian surgical methods
 - bilateral laparoscopic ovarian drilling (BLOD), 112
 - laparoscopic ovarian multi-needle intervention, 113
- laser, 111
- transvaginal hydrolaparoscopy (THL), 112
- ultrasound-guided transvaginal ovarian needle drilling (UTND), 112–113
- unilateral laparoscopic ovarian drilling (ULOD), 112
- unipolar diathermy, 110
- patient perspective (PCOS), 186–188
- phenome-wide association studies (PheWAS)
 - links to obesity and depression, 59
- phenotypical risk score (PPRS), 16–17
- polygenic risk score (PRS), 15–16, 18
- phenotypes in international classification criteria (2018), 49
- phenotypical risk score (PPRS), 16–17
- polycystic ovarian morphology (PCOM)
 - defined, 8
 - risks associated with, 8
- polycystic ovarian morphology (PCOM) ultrasound
 - definitions
 - current guidelines for, 32–33
 - early, 30–31
 - Rotterdam criteria, 30–31
 - summary of, 31
- polycystic ovarian morphology (PCOM) ultrasound
 - physiological considerations
- adolescent reproductive transition stage, 39–40
- ovary as biomarker, 41–42
- reproductive aging, 40–41
- polycystic ovary syndrome (PCOS)
 - bariatric surgery for, 155–156, 157
 - defined, 8
 - hyperandrogenism, 121–122
 - obesity, 122–123
 - prevalence of, 121
 - reproductive health, 122
- polycystic ovary syndrome (PCOS)
 - adverse pregnancy outcomes
- adhesions, 113–114
- gestational diabetes mellitus (GDM), 133
- ovarian failure, 114–115
- overview, 133
- placental morphology, 135–136
- preeclampsia (PE), 133–134
- preterm birth, 134–135
- polycystic ovary syndrome (PCOS)
 - and adrenal system
- adrenal androgen
 - steroidogenesis, 67–68
- complex pathophysiology of, 67
- DHEAS as validator of dysfunction, 69
- effects of extra adrenal androgen on steroidogenesis, 72–75
- epidemiology of adrenal androgen excess, 68–69
- oxygenated adrenal androgens, 69
- prevalence of, 67
- in vivo characterization of, 70–72
- polycystic ovary syndrome (PCOS)
 - and cancer
- breast cancer, 193
- endometrial cancer, 189–193
- ovarian cancer, 195
- polycystic ovary syndrome (PCOS)
 - and offspring health
- biomarkers, 139
- neonatal outcomes, 136
- offspring follow-up, 136–139

Index

- polycystic ovary syndrome (PCOS)
 - classification (2018)
 - anti-Müllerian hormone (AMH), 48
 - ethnic variation, 48–49
 - hyperandrogenism, 46–48
 - menopause and, 49
 - menstrual irregularity, 45–46
 - phenotypes, 49
 - precursors to, 45
 - ultrasound, 48
- polycystic ovary syndrome (PCOS)
 - environmental factors
 - endocrine disruptive chemicals (EDCs) and, 83–89
 - endocrine disruptive chemicals (EDCs) background, 80–83
- polycystic ovary syndrome (PCOS)
 - epidemiology
 - with diagnostic criteria, 21–22
 - guidelines for, 26
 - race and ethnicity, 26
 - in referral populations, 22–23
 - in unbiased populations, 23–26
- polycystic ovary syndrome (PCOS)
 - history
 - development from ovarian pathology to multisystem endocrine disease, 4–6
 - development of diagnostic criteria, 3
 - natural selection and, 6
 - references to, 1
- polycystic ovary syndrome (PCOS)
 - in utero
 - etiology of, 58
 - anti-Müllerian hormone (AMH) role, 63–64
 - epigenetic etiology, 60–62
 - genetic inheritance, 59–60
 - perinatal exposure, 85–86
- polycystic ovary syndrome (PCOS)
 - in vitro fertilization
 - superovulation strategies, 124–127
 - as third-line treatment, 121
- polycystic ovary syndrome (PCOS)
 - lifestyle guidance
 - behavior modification strategies, 95–96
 - dietary recommendations, 94
 - health literacy, 98–100
 - importance of, 92–93, 122
 - management of healthy lifestyle, 94–95
 - obesity, 93–94
 - support groups, 100
- polycystic ovary syndrome (PCOS)
 - long-term health disorders
 - cardiovascular disease (CVD), 174–176
 - endometrial cancer, 179–180
 - gestational diabetes mellitus (GDM), 172
 - hyperinsulinemia, 171
 - metabolic syndrome, 172
 - obesity, 172–174
 - obstructive sleep apnea (OSA), 176–177
 - on offspring, 172
 - quality of life studies, 178
 - summary of studies on, 170
 - type 2 diabetes, 171–172
- polycystic ovary syndrome (PCOS)
 - mental health disorders
 - anxiety, 165, 177–178
 - depression, 162–165, 177–178
 - eating disorders (ED), 166, 178
 - in offspring, 179
 - psychosexual dysfunction, 178
 - psychosis, 178
- polycystic ovary syndrome (PCOS)
 - ovarian surgery. *See also* bilateral ovarian wedge resection (BOWR)
 - cost analysis, 115
 - history of, 110
 - mechanisms of action, 115–116
 - methods of, 110–113
- polycystic ovary syndrome (PCOS)
 - ovarian surgery complications
 - adhesions, 113–114
 - ovarian failure, 114–115
- polycystic ovary syndrome (PCOS)
 - ovarian surgery efficacy
 - consensus expert opinion, 116
 - metanalyses, 116
- polycystic ovary syndrome (PCOS)
 - ovulation induction
 - clinical treatment, 105–108
 - lifestyle interventions, 102
 - pharmacologic interventions, 103–105
 - prevalence of, 102
- polycystic ovary syndrome (PCOS)
 - patient perspective, 186–188
- polycystic ovary syndrome (PCOS)
 - treatment
 - anovulation, 106–108
 - bilateral ovarian wedge resection (BOWR), 2–3
 - exercise, 96–98
 - health literacy, 98–100
 - IVF, 121
 - key patient messages for, 98
 - ovulation induction, 105–108
- polycystic ovary syndrome (PCOS)
 - ultrasound
 - 2D offline imaging, 36–37
 - 2D real-time imaging, 34–36
 - 3D imaging, 36–39
 - transabdominal ultrasonography (TAUS), 29
- adolescent reproductive transition stage, 39–40
- anti-Müllerian hormone (AMH), 34
- historical development of diagnostic criteria, 3
- history of, 29–30
- in international classification criteria (2018), 48
- laparoscopic ovarian multi-needle intervention, 113
- ovarian stroma, 33
- ovary as biomarker, 41–42
- PCOM definitions in, 30–33
- reproductive aging, 40–41
- Rotterdam criteria and, 30
- string of pearls follicle distribution, 33–34, 35
- technical assessment for, 34–39
- ultrasound-guided transvaginal ovarian needle drilling (UTND), 112–113
- vascular indices, 34
- polygenic risk score (PRS), 15–16, 18
- preeclampsia (PE), 133–134
- pregnancy, normal fertilization, 142–143
- in vivo oocyte maturation process, 142
- pre-ovulatory trigger in IVF, 125, 144
- preterm birth and PCOS, 134–135
- psychosexual dysfunction, 178
- psychosis and PCOS, 178
- quality of life studies, 178
- race and PCOS, 26
- reproductive aging and PCOS, 40–41
- reproductive stage and PCOS, 39–40
- Rotterdam criteria, 3
 - algorithm, 45
 - defined, 121
 - history of, 4
 - regional variations of, 50
 - transvaginal ultrasonography (TVUS) definitions, 30–31
 - ultrasound and, 30
- Roux-en-Y gastric bypass, 153
- set point (obesity), 151
- sex hormone-binding globulin (SHBG), 10
- single nucleotide polymorphisms (SNP)
 - associated with PCOS, 12
 - effect in genes, 8, 13

Soranus of Ephesus, 1	transabdominal ultrasonography (TAUS), 29	string of pearls follicle distribution, 33–34
Stein, Irving	transvaginal hydrolaparoscopy (THL), 112	vascular indices, 34
1935 paper of, 2	transvaginal ultrasonography (TVUS)	trigger injection for ovulation, 125, 144
bilateral ovarian wedge resection (BOWR), 110	anti-Müllerian hormone (AMH), 34	
biography of, 1	controversy in, 31–32	ultrasound-guided transvaginal ovarian needle drilling (UTND), 112–113
research of, 1–2	history of, 30	unilateral laparoscopic ovarian drilling (ULOD), 112
Stein-Leventhal syndrome, 45	ovarian stroma, 33	unipolar diathermy, 110
string of pearls follicle distribution, 33–34, 35	PCOM definitions in, 30–33	
support groups in PCOS, 100		